ANGIOTENSIN ll ACETATE (angiotensin ii) by Gland Pharma is release. First approved in 2025.
Drug data last refreshed 20h ago
release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein coupled-angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.
Vasoconstrictor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
Worked on ANGIOTENSIN ll ACETATE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.